Androgen and estrogen receptors: Potential of crystallography in the fight against cancer

International Journal of Biochemistry and Cell Biology

Volumn 39, Issue 7-8, 2007, Pages 1280-1287

  Nahoum, Virginie ^a,b,c   Bourguet, William ^a,b,c  

^a CNRS   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Androgen; Cancer; Estrogen; Nuclear receptor; Structure

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; ESTROGEN RECEPTOR; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

CRYSTALLOGRAPHY; HORMONE BINDING; PROTEIN MOTIF; PROTEIN STRUCTURE; SHORT SURVEY;

CRYSTALLOGRAPHY, X-RAY; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 34447097728     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2007.01.001     Document Type: Short Survey

References (37)

1. Baek S.H., Ohgi K.A., Nelson C.A., Welsbie D., Chen C., Sawyers C.L., et al. Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 103 9 (2006) 3100-3105
2. Bohl C.E., Gao W., Miller D.D., Bell C.E., and Dalton J.T. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America 102 17 (2005) 6201-6206
3. Bohl C.E., Miller D.D., Chen J., Bell C.E., and Dalton J.T. Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. Journal of Biological Chemistry 280 45 (2005) 37747-37754
4. Bourguet W., Germain P., and Gronemeyer H. Nuclear receptor ligand-binding domains: Three-dimensional structures, molecular interactions and pharmacological implications. Trends in Pharmacological Sciences 21 10 (2000) 381-388
5. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 6652 (1997) 753-758
6. Dubbink H.J., Hersmus R., Verma C.S., van der Korput H.A., Berrevoets C.A., van Tol J., et al. Distinct recognition modes of FXXLF and LXXLL motifs by the androgen receptor. Molecular Endocrinology 18 9 (2004) 2132-2150
7. Estebanez-Perpina E., Moore J.M., Mar E., Delgado-Rodrigues E., Nguyen P., Baxter J.D., et al. The molecular mechanisms of coactivator utilization in ligand-dependent transactivation by the androgen receptor. Journal of Biological Chemistry 280 9 (2005) 8060-8068
8. Germain P., Staels B., Dacquet C., Spedding M., and Laudet V. Overview of nomenclature of nuclear receptors. Pharmacological Reviews 58 4 (2006) 685-704
9. Gronemeyer H., Gustafsson J.A., and Laudet V. Principles for modulation of the nuclear receptor superfamily. Nature Reviews Drug Discovery 3 11 (2004) 950-964
10. Hall J.M., and McDonnell D.P. Coregulators in nuclear estrogen receptor action: From concept to therapeutic targeting. Molecular Interventions 5 6 (2005) 343-357
11. He B., Gampe Jr. R.T., Hnat A.T., Faggart J.L., Minges J.T., French F.S., et al. Probing the functional link between androgen receptor coactivator and ligand-binding sites in prostate cancer and androgen insensitivity. Journal of Biological Chemistry 281 10 (2006) 6648-6663
12. He B., Gampe Jr. R.T., Kole A.J., Hnat A.T., Stanley T.B., An G., et al. Structural basis for androgen receptor interdomain and coactivator interactions suggests a transition in nuclear receptor activation function dominance. Molecular Cell 16 3 (2004) 425-438
13. 2-terminal interaction with the ligand binding domain of the androgen receptor. Journal of Biological Chemistry 275 30 (2000) 22986-22994
14. He B., Minges J.T., Lee L.W., and Wilson E.M. The FXXLF motif mediates androgen receptor-specific interactions with coregulators. Journal of Biological Chemistry 277 12 (2002) 10226-10235
15. Hur E., Pfaff S.J., Payne E.S., Gron H., Buehrer B.M., and Fletterick R.J. Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biology 2 9 (2004) E274
16. Jensen E.V., and Jordan V.C. The estrogen receptor: A model for molecular medicine. Clinical Cancer Research 9 6 (2003) 1980-1989
17. Kong E.H., Heldring N., Gustafsson J.A., Treuter E., Hubbard R.E., and Pike A.C. Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor. Proceedings of the National Academy of Sciences of the United States of America 102 10 (2005) 3593-3598
18. Leduc A.M., Trent J.O., Wittliff J.L., Bramlett K.S., Briggs S.L., Chirgadze N.Y., et al. Helix-stabilized cyclic peptides as selective inhibitors of steroid receptor-coactivator interactions. Proceedings of the National Academy of Sciences of the United States of America 100 20 (2003) 11273-11278
19. Lumbroso S., Wagschal A., Bourguet W., Georget V., Mazen I., Servant N., et al. A new mutation of the androgen receptor, P817A, causing partial androgen insensitivity syndrome: In vitro and structural analysis. Journal of Molecular Endocrinology 32 3 (2004) 679-687
20. Manas E.S., Xu Z.B., Unwalla R.J., and Somers W.S. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Structure 12 12 (2004) 2197-2207
21. Matias P.M., Carrondo M.A., Coelho R., Thomaz M., Zhao X.Y., Wegg A., et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(ccr)) derived from an androgen-independent prostate cancer. Journal of Medicinal Chemistry 45 7 (2002) 1439-1446
22. Matias P.M., Donner P., Coelho R., Thomaz M., Peixoto C., Macedo S., et al. Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. Journal of Biological Chemistry 275 34 (2000) 26164-26171
23. Metivier R., Reid G., and Gannon F. Transcription in four dimensions: Nuclear receptor-directed initiation of gene expression. EMBO Reports 7 2 (2006) 161-167
24. Nettles K.W., Sun J., Radek J.T., Sheng S., Rodriguez A.L., Katzenellenbogen J.A., et al. Allosteric control of ligand selectivity between estrogen receptors alpha and beta: Implications for other nuclear receptors. Molecular Cell 13 3 (2004) 317-327
25. Perissi V., and Rosenfeld M.G. Controlling nuclear receptors: The circular logic of cofactor cycles. Nature Reviews Molecular Cell Biology 6 7 (2005) 542-554
26. Pike A.C. Lessons learnt from structural studies of the oestrogen receptor. Best Practice and Research Clinical Endocrinology and Metabolism 20 1 (2006) 1-14
27. Pike A.C., Brzozowski A.M., Hubbard R.E., Bonn T., Thorsell A.G., Engstrom O., et al. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO Journal 18 17 (1999) 4608-4618
28. Pike A.C., Brzozowski A.M., Walton J., Hubbard R.E., Thorsell A.G., Li Y.L., et al. Structural insights into the mode of action of a pure antiestrogen. Structure 9 2 (2001) 145-153
29. Sack J.S., Kish K.F., Wang C., Attar R.M., Kiefer S.E., An Y., et al. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proceedings of the National Academy of Sciences of the United States of America 98 9 (2001) 4904-4909
30. Salvati M.E., Balog A., Shan W., Wei D.D., Pickering D., Attar R.M., et al. Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists. Bioorganic and Medicinal Chemistry Letters 15 2 (2005) 271-276
31. Shiau A.K., Barstad D., Loria P.M., Cheng L., Kushner P.J., Agard D.A., et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95 7 (1998) 927-937
32. Shiau A.K., Barstad D., Radek J.T., Meyers M.J., Nettles K.W., Katzenellenbogen B.S., et al. Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nature Structural Biology 9 5 (2002) 359-364
33. Smith C.L., and O'Malley B.W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 1 (2004) 45-71
34. Taplin M.E., and Balk S.P. Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence. Journal of Cellular Biochemistry 91 3 (2004) 483-490
35. Todo T., Ikeuchi T., Kobayashi T., and Nagahama Y. Fish androgen receptor: cDNA cloning, steroid activation of transcription in transfected mammalian cells, and tissue mRNA levels. Biochemical and Biophysical Research Communications 254 2 (1999) 378-383
36. Wu Y.L., Yang X., Ren Z., McDonnell D.P., Norris J.D., Willson T.M., et al. Structural basis for an unexpected mode of SERM-mediated ER antagonism. Molecular Cell 18 4 (2005) 413-424
37. Xu H.E., Stanley T.B., Montana V.G., Lambert M.H., Shearer B.G., Cobb J.E., et al. Structural basis for antagonist-mediated recruitment of nuclear co-repressors by PPARalpha. Nature 415 6873 (2002) 813-817